IDYA - IDEAYA Biosciences, Inc.

31.83
-1.770   -5.561%

Share volume: 1,391,884
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$33.60
-1.77
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
5%
Profitability 0%
Dept financing 2%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.35%
1 Month
6.19%
3 Months
-6.69%
6 Months
15.07%
1 Year
84.82%
2 Year
-10.61%
Key data
Stock price
$31.83
P/E Ratio 
0.00
DAY RANGE
$31.26 - $33.56
EPS 
-$1.28
52 WEEK RANGE
$16.82 - $39.28
52 WEEK CHANGE
$80.35
MARKET CAP 
3.031 B
YIELD 
N/A
SHARES OUTSTANDING 
87.814 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-05-2025
BETA 
1.24
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,284,183
AVERAGE 30 VOLUME 
$1,750,872
Company detail
CEO: Yujiro S. Hata
Region: US
Website: ideayabio.com
Employees: 80
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

IDEAYA Biosciences, Inc. focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions.

Recent news